CBL-514: The Fat-Cell-Killing Injection, Fact-Checked
A viral post says CBL-514 cut deep visceral fat 12% in four weeks and could replace weight-loss drugs. The published trials tell a narrower story: a spot treatment for the fat under your skin, tested in people whose weight didn't change.
How It Works
CBL-514 is a small-molecule drug injected straight into the abdominal fat layer on a grid (2 mg per cm², up to 600 mg per session). The sponsor's lab work, described in the phase 2a paper, says it blocks a survival enzyme called DYRK1b and switches on cell-death signals (caspase-3, Bax/Bcl-2), so treated fat cells undergo apoptosis (programmed cell death). That lab data is the sponsor's own and unpublished.
The phase 2a and phase 2 trials enrolled people with a BMI between 18.5 and 35 and asked them to keep their weight stable; the phase 2a study dropped anyone whose weight changed by 5% or more. In the 2025 phase 2 trial, body weight barely moved (+0.45 kg on CBL-514). The fat reduction was measured in the treated patch of belly, not across the body.
GLP-1 drugs act on the whole body through appetite and metabolism. In STEP 1, semaglutide 2.4 mg cut body weight by a mean 14.9% over 68 weeks, vs 2.4% on placebo. CBL-514 targets one area and isn't designed to change body weight. The two answer different questions: 'lose weight' vs 'reshape one spot.'
A 2008 Nature study found adults keep a roughly constant number of fat cells, even after major weight loss, and replace about 10% of them every year. Whether a patch cleared by CBL-514 stays cleared is unknown: the trials followed people for only 8 to 12 weeks after their last treatment.
What the Data Shows
Key Takeaways
- CBL-514 is an experimental small-molecule injection from Caliway Biopharmaceuticals that is reported to trigger apoptosis in fat cells at the injection site.
- In a 108-person phase 2b trial, 76.7% of CBL-514 participants improved by at least one grade on a clinician belly-fat scale vs 18.9% on placebo, and MRI showed a mean 20.3% drop in abdominal fat volume.
- In a 76-person phase 2 trial, 69.6% on CBL-514 lost at least 150 mL of subcutaneous belly fat 8 weeks after their last dose; no one on placebo did.
- Body weight stayed essentially flat: the results reflect a local fat reduction, not weight loss.
- In a small phase 2a study of Dercum's disease (painful fatty lumps), lipomas shrank by a median 45–59% and pain scores dropped; the FDA has granted it Fast Track status for that condition.
- The main side effects were injection-site reactions (pain, swelling, redness, bruising), mostly mild to moderate and short-lived.
- Whether CBL-514 affects visceral fat (the deep fat around the organs): none of the four published trials reports a visceral-fat outcome.
- Whether it treats obesity, diabetes or blood pressure: the trials measured fat volume, rating scales and safety, not metabolic outcomes.
- Whether results last: follow-up ended 8 to 12 weeks after the final treatment.
- How it compares head-to-head with deoxycholic acid (Kybella), cryolipolysis or liposuction.
- Long-term safety in larger, more diverse groups: participants were mostly women, and about half of phase 2 enrollees didn't complete the study.
- When, or whether, it will be approved: it is still investigational.
Frequently Asked Questions
What is CBL-514?
CBL-514 is an investigational injectable drug developed by Caliway Biopharmaceuticals. It is injected into a patch of subcutaneous fat, the layer you can pinch, and is reported to make the fat cells there self-destruct through apoptosis (programmed cell death) instead of just shrinking. It has completed phase 2 trials for abdominal fat and for the lipomas of Dercum's disease. It is not approved for sale.
Does CBL-514 really cut visceral fat by 12% in four weeks?
We could not verify that claim. The four CBL-514 trials published in peer-reviewed journals (2022–2026) measured subcutaneous belly fat by ultrasound or MRI, or the size of lipomas in Dercum's disease. None reports a visceral-fat result. A conference abstract may exist, but no peer-reviewed paper we could find supports the '12% visceral fat in 4 weeks' figure.
Is CBL-514 a weight-loss drug like Ozempic?
No. Semaglutide (Ozempic/Wegovy) works on the whole body through appetite and metabolism and cut body weight by a mean 14.9% over 68 weeks in STEP 1. The CBL-514 trials asked participants to keep their weight stable, and average body weight barely changed (+0.45 kg at the 4-week follow-up in the 2025 phase 2 trial). It is a body-contouring treatment for one area.
Are fat cells destroyed by CBL-514 gone for good?
Nobody knows yet. Research using carbon dating found that adults replace about 10% of their fat cells every year while keeping the total number roughly constant. The CBL-514 trials ended 8 to 12 weeks after the last treatment, so how long the effect lasts hasn't been measured.
What are the side effects of CBL-514?
In the published trials the most common side effects were injection-site reactions: pain, swelling, redness, bruising and itching, mostly mild to moderate. In the 2025 phase 2 trial, pain resolved within a week for 90.5% of those who had it. No serious adverse events were reported in the Dercum's study.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
CBL-514 is an investigational drug that is not approved by the FDA or any regulator for sale. All CBL-514 trial figures come from sponsor-funded phase 2 trials. Talk to a licensed clinician about any fat-reduction treatment.